Gregory M. Lanza

Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS (2008)

Waters, Emily A, Chen, Junjie, Allen, John S, Zhang, Huiying, Lanza, Gregory M, Wickline, Samuel A

Abstract Background Angiogenesis is a critical early feature of atherosclerotic plaque development and may also feature prominently in the pathogenesis of aortic valve stenosis. It has been shown...

Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics

Tran, Trung D, Caruthers, Shelton D, Hughes, Michael, Marsh, John N, Cyrus, Tillmann, Winter, Patrick M, ...

Molecular imaging is a novel tool that has allowed non-invasive diagnostic imaging to transition from gross anatomical description to identification of specific tissue epitopes and observation of...

Minute dosages of ανβ3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits

Winter, Patrick M., Schmieder, Anne H., Caruthers, Shelton D., Keene, Jeffery L., Zhang, Huiying, Wickline, Samuel A., ...

Fumagillin suppresses angiogenesis in cancer models and clinical trials, but it is associated with neurotoxicity at systemic doses. In this study, ανβ3-targeted fumagillin nanoparticles were used...

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

Soman, Neelesh R., Baldwin, Steven L., Hu, Grace, Marsh, Jon N., Lanza, Gregory M., Heuser, John E., ...

The in vivo application of cytolytic peptides for cancer therapeutics is hampered by toxicity, nonspecificity, and degradation. We previously developed a specific strategy to synthesize a nanoscale...